Is Marksans Pharma overvalued or undervalued?

Sep 23 2025 08:04 AM IST
share
Share Via
As of September 22, 2025, Marksans Pharma is fairly valued with a PE ratio of 22.53, an EV to EBITDA of 14.97, and a ROCE of 21.42%, making it more attractive than peers like Sun Pharma and Divi's Lab, despite underperforming the Sensex with a year-to-date decline of 41.18%.
As of 22 September 2025, the valuation grade for Marksans Pharma has moved from expensive to fair. The company is currently fairly valued based on its financial metrics. Key ratios include a PE ratio of 22.53, an EV to EBITDA of 14.97, and a ROCE of 21.42%.

In comparison to its peers, Marksans Pharma's PE ratio is significantly lower than Sun Pharma's 34.24 and Divi's Lab's 70.06, both categorized as expensive. Additionally, it is more favorable than Dr. Reddy's Labs, which has a PE of 19.13 and is considered attractive. Recent stock performance shows that Marksans Pharma has underperformed the Sensex year-to-date, with a decline of 41.18% compared to a 5.15% increase in the index.
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News